Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis

ST. LOUIS, MO, February 22, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today announced that it has entered into an exclusive license agreement…

Read More

Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company’s Global NK and T cell Clinical Programs

ST. LOUIS, February 22, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of Jan Davidson M.D., Ph.D., as the company’s…

Read More

Wugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline

ST. LOUIS, Nov. 19, 2020 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ryan Sullivan, Ph.D., as Vice President and Head of…

Read More

Wugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion

ST. LOUIS, April 30, 2019 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Mark Lewis, Ph.D., as Vice President of Finance…

Read More

WUGEN Expands Leadership Team with Appointment of a Vice President of Research and Development and a Vice President of Product Development

ST. LOUIS, March 26, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ayman Kabakibi, Ph.D., as Vice President of Research and…

Read More

WUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR

ST. LOUIS, Feb. 20, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced data presentations at the 2019 Transplantation & Cellular Therapy (TCT) Meetings…

Read More

WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting

ST. LOUIS, Dec. 3, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform.…

Read More

WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis

ST. LOUIS, Nov. 13, 2018 /PRNewswire/ --  WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into an exclusive license agreement with Washington…

Read More

WUGEN Announces Presentations at American Society of Hematology Annual Meeting

ST. LOUIS, Nov. 1, 2018  /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN platform were accepted for an…

Read More